BIOMAT Database Logo BIOMAT Database Logo

Aberrant sexual behaviours in Parkinson's disease during dopaminergic treatment. 2007

Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D012735 Sexual Dysfunction, Physiological Physiological disturbances in normal sexual performance in either the male or the female. Sex Disorders,Sexual Disorders, Physiological,Sexual Dysfunctions, Physiological,Physiological Sexual Disorder,Physiological Sexual Disorders,Physiological Sexual Dysfunction,Physiological Sexual Dysfunctions,Sexual Disorder, Physiological
D015259 Dopamine Agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. Dopamine Drugs,Dopamine Effect,Dopamine Effects,Dopaminergic Agents,Dopaminergic Drugs,Dopaminergic Effect,Dopaminergic Effects,Agents, Dopamine,Agents, Dopaminergic,Drugs, Dopamine,Drugs, Dopaminergic,Effect, Dopamine,Effect, Dopaminergic,Effects, Dopamine,Effects, Dopaminergic

Related Publications

Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.
December 2015, EMBO molecular medicine,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.
November 2022, Brain : a journal of neurology,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Initiating dopaminergic treatment in Parkinson's disease.
September 2014, Lancet (London, England),
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Non-dopaminergic drug treatment of Parkinson's disease.
April 2001, Expert opinion on pharmacotherapy,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Dopaminergic agonists in the treatment of Parkinson's disease.
October 1990, Neurology,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
[Dopaminergic agonists in the treatment of Parkinson's disease].
December 2000, Revue medicale de Bruxelles,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Dopaminergic agonists in the treatment of Parkinson's disease.
May 1992, Neurologic clinics,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
The dark side of dopaminergic therapies in Parkinson's disease: shedding light on aberrant salience.
December 2018, CNS spectrums,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.
January 2019, Frontiers in pharmacology,
Antonino Cannas, and Paolo Solla, and Gian Luca Floris, and Giulia Serra, and Paolo Tacconi, and Maria Giovanna Marrosu
Dopaminergic agonists in Parkinson's disease.
May 2014, Neurologia (Barcelona, Spain),
Copied contents to your clipboard!